Transcatheter aortic valve implant (TAVI) is gaining momentum in the treatment of severe, symptomatic aortic valve stenosis, and its indication is expanding to lower surgical risk individuals, who are generally younger and have a long life expectancy. Therefore, transcatheter bioprostheses durability appears of critical importance. Aim of the present study is to evaluate mid-term outcomes of TAVI in a high-volume single center cohort.

Transcatheter aortic bioprosthesis durability: A single center experience / Moroni, Francesco; Ziviello, Francesca; Federico, Francesco; Di Stefano, Daniele; Beneduce, Alessandro; Vella, Ciro Salvatore; Ancona, Francesco; Ingallina, Giacomo; Ancona, Marco; Ferri, Luca A; Russo, Filippo; Bellini, Barbara; Agricola, Eustachio; Chieffo, Alaide; Montorfano, Matteo. - In: CARDIOVASCULAR REVASCULARIZATION MEDICINE. - ISSN 1553-8389. - (2022). [Epub ahead of print] [10.1016/j.carrev.2022.05.011]

Transcatheter aortic bioprosthesis durability: A single center experience

Moroni, Francesco;Agricola, Eustachio;Chieffo, Alaide;Montorfano, Matteo
2022-01-01

Abstract

Transcatheter aortic valve implant (TAVI) is gaining momentum in the treatment of severe, symptomatic aortic valve stenosis, and its indication is expanding to lower surgical risk individuals, who are generally younger and have a long life expectancy. Therefore, transcatheter bioprostheses durability appears of critical importance. Aim of the present study is to evaluate mid-term outcomes of TAVI in a high-volume single center cohort.
2022
Bioprosthesis
Bioprosthesis degeneration
TAVI
TAVI durability
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/130352
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact